On this page
When you stain an onion peel or cheek cells in the school lab, the dye colours some parts and not others. Paul Ehrlich spent his career asking why, and that question led to two big ideas: that antibodies bind to specific targets, and that a drug could be designed to hit a germ while leaving the patient alone. This post covers who he was, how a dye chemist became a founder of chemotherapy, the story of compound 606, and what students can learn from his method.
Who was Paul Ehrlich?
Ehrlich was born on 14 March 1854 in Strehlen, then in Prussia and now Strzelin in Poland, and died at Bad Homburg on 20 August 1915, according to his Nobel Prize biography. His doctoral thesis in 1878 was on the theory and practice of staining animal tissues, inspired by the new aniline dyes. He showed that the dyes could be grouped as acidic, basic or neutral, and his staining of granules in blood cells laid foundations for haematology. In 1882 he published a method for staining the tuberculosis bacterium that Robert Koch had just discovered; the biography notes that the later Ziehl-Neelsen stain was built on it.
Why did dyes lead to the idea of a magic bullet?
The Science History Institute explains the link. Ehrlich noticed that dyes react specifically with particular parts of cells. If a dye could seek out one structure, a chemical could perhaps seek out one microbe. In 1906, the Institute notes, he predicted that chemists would soon make substances that seek out specific disease-causing agents. He called them "magic bullets."
His Nobel biography puts his aim this way: to find chemicals with special affinity for pathogenic organisms, which would go straight to them as antitoxins go to their toxins.
What did he win the Nobel Prize for?
The 1908 Nobel Prize in Physiology or Medicine was shared by Ehrlich and Ilya Mechnikov "in recognition of their work on immunity." Working in Robert Koch's institute in Berlin in the 1890s, Ehrlich helped make Emil von Behring's diphtheria antitoxin reliable. His biography credits him with establishing a fixed standard so that the strength of each batch of serum could be measured in units, the basis for later standardisation of sera.
He explained antibodies with his side-chain theory. As the facts page summarises it, cells carry receptor-like side chains that bind harmful substances; extra side chains break off and circulate as antibodies. The details have changed, but the core idea of a specific receptor binding a specific molecule is central to immunology today. Our guide to human health and immunity covers antibodies for your syllabus.
How was compound 606 found?
In Frankfurt, Ehrlich ran an institute for experimental therapy and, from 1906, the Georg-Speyer-Haus for chemotherapy, the Science History Institute records. His team, including the chemist Alfred Bertheim, began with an arsenic compound called atoxyl and made a long series of related compounds.
The bacterium that causes syphilis had just been identified. The Nobel biography tells what happened next. Compound number 606 in the series had been set aside in 1907 as ineffective. Then Sahachiro Hata, sent by Ehrlich's former colleague Kitasato, arrived having learned to infect rabbits with syphilis. Ehrlich asked him to test the discarded drug, and Hata found it very effective. After hundreds of repeated experiments, Ehrlich announced it as Salvarsan. The Science History Institute dates the discovery to 1909 and records that Salvarsan, and the easier-to-use Neosalvarsan of 1912 (compound 914), remained the most effective syphilis treatments until antibiotics replaced them.
What does "606" tell you about drug discovery?
Think about what the number means. If each compound took, say, two days to make and test, 606 compounds would take 1,212 working days, more than three years at about 300 working days a year. Those working-day figures are only an illustration, but the scale is real: the Science History Institute describes three years and three hundred syntheses as "an amazingly large number" for the time. Ehrlich's real innovation was method: a clear target, a family of related molecules and patient, systematic testing.
The approach also had costs. His biography notes that Salvarsan met strong opposition before doctors accepted it. Strebhardt and Ullrich's review, Paul Ehrlich's magic bullet concept: 100 years of progress (2008), traces how the same goal of a drug aimed at a precise molecular target still drives modern cancer drug design.
What can a student take from how Ehrlich worked?
Start from a small, odd observation. Why one dye stains one cell type became a theory of drugs.
Turn an idea into a test you can repeat. He insisted, his biography says, on repeated proof before publishing.
Revisit what you discarded. Compound 606 had been written off until a better test came along.
Work with people who have the skills you lack. Hata's rabbit model was the missing piece.
Ehrlich's research rested on chemistry, biology and careful counting at once. When a question in your own study crosses subjects, the Fermi Concept Library covers every concept in physics, chemistry, biology, mathematics and computing, so you can follow the thread from one to the next. For the next chapter of the story, read about Alexander Fleming and penicillin and Gertrude Elion's approach to drug design.
Try this: in your next practical, note which parts of the cell take up the stain, and write one line on why a dye might bind to one structure and not another.
